blindness from tirzepatide Vision loss risks in patients using popular GLP-1 medications raise concerns Tirzepatide and Macular Degeneration: Current

In this situation, medical evaluation is needed to check kidney function

Grigson : If our data show that it is safe and is saving lives, it might be possible to move it quickly through the FDA, but we will have to wait to see what will happen

The lowest dose of 2.5 mg tirzepatide was the initiation dose for all patients and the dosages were up titrated and adjusted by the physicians based on individual patients glycemic and/or weight loss goal and adverse events of the treatment

However, some patients may benefit from temporary discontinuation, particularly those: In the dose-escalation phase Experiencing significant gastrointestinal symptoms With known gastroparesis or other conditions affecting gastric emptying With obesity complicated by GERD or hiatal hernia Undergoing procedures with higher aspiration risk For these higher-risk patients on once-weekly injectable semaglutide , some clinicians recommend discontinuation approximately one week (7 days) before elective surgery

This may help some patients experience more reliable results, especially those who have digestive issues or find it hard to absorb oral medications